Joe Anderson has been appointed manager of Abingworth Management’s quoted biotech investments, and will also contribute to deals in unquoted companies.
Anderson, who has spent most of his career as an analyst and portfolio manager in the pharmaceutical and bioscience sectors, joins Abingworth from First State Investments – part of Commonwealth Bank of Australia – where he launched and headed the firm’s global health and biotechnology fund.
Previously, Anderson was a pan-European pharmaceuticals analyst at Dresdner Kleinwort Benson and head of the policy unit at the Wellcome Trust, where he led a team researching and advising the board on funding initiatives in medical research.
“The role enables me to combine insights on public and private equities in life sciences at a time when quoted and unquoted companies are becoming increasingly interdependent,” said Anderson.
Abingworth has offices in London, Cambridge (UK) and Palo Alto, and has funds under management of more than $700 million. It has backed more than 80 life science and medical firms.